Insider screener

Period: 12 months Role: Other officers × + Add filter Clear all
Saved screens

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

23,078 decisions over 12 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

23,078 decisions over 12 months Remove this filter
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

23,078 decisions over 12 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

23,078 decisions over 12 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
23,078 decisions over 12 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
23,078 decisions over 12 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

23,078 decisions over 12 months
Stock
Insider
Type ?
Why it stands out
3 Feb 2026
Michael S. Cuffe EVP and Chief Clinical Officer
Sold at will
$747.14K 1,500 at 498.09
4.8%
Not planned
3 Feb 2026
Margaret Hayne Co-President & CCO · indirect
Sold on a plan 2×
$675.54K 9,333 at 72.38
0.5%
Planned (10b5-1)
3 Feb 2026
Craig E Hunsaker EVP, People & Culture
Sold on a plan
$549.54K 37,358 at 14.71
3.1%
Planned (10b5-1)
3 Feb 2026
Gary W Staley SVP Global Sales NSE
Sold at will
$537.63K 20,742 at 25.92
10.2%
Not planned
3 Feb 2026
William E. Rote Chief Research Officer
Sold on a plan
$409.10K 12,446 at 32.87
10.2%
Planned (10b5-1)
3 Feb 2026
Kimberly Anne Kellermann SVP, Chief Operations Officer
Sold at will
$379.03K 5,265 at 71.99
47.5%
Not planned
3 Feb 2026
Solomon Moshkevich President, Clinicaldiagnostics
Sold on a plan
$378.23K 1,639 at 230.77
1.2%
Planned (10b5-1)
3 Feb 2026
James P Williams SVP-CHRO
Sold at will
$352.17K 5,243 at 67.17
9.7%
Not planned
3 Feb 2026
Daniel Rabinowitz Sec. and Chief Legal Officer
Sold on a plan
$307.84K 1,334 at 230.77
0.6%
Planned (10b5-1)
3 Feb 2026
Mary Clara Capel Retired Board Member
Sold at will
$296.55K 5,000 at 59.31
19.7%
Not planned
3 Feb 2026
Brian K Chaney Senior Vice President
Sold at will
$288.04K 11,157 at 25.82
11.2%
Not planned
3 Feb 2026
Riccardo Procacci Senior Vice President
Sold at will
$248.09K 800 at 310.11
4.8%
Not planned
3 Feb 2026
Peter Heerma Chief Commercial Officer
Sold at will
$234.80K 7,310 at 32.12
5.3%
Not planned
3 Feb 2026
Elizabeth E Reed Chief Legal Officer and GC
Sold at will
$230.46K 7,175 at 32.12
6.2%
Not planned
3 Feb 2026
Adam Crystal President, R&D
Sold at will 2×
$226.30K 18,452 at 12.26
9.0%
Not planned
3 Feb 2026
Jula Inrig Chief Medical Officer
Sold at will
$223.43K 6,956 at 32.12
6.1%
Not planned
3 Feb 2026
Bala Sathyanarayanan EVP, Chief Human Resources Off
Sold at will
$180.65K 2,499 at 72.29
5.0%
Not planned
3 Feb 2026
Ritadhwaja Jebens Singh EVP & Chief Digital Officer
Sold on a plan
$178.22K 5,880 at 30.31
5.4%
Planned (10b5-1)
3 Feb 2026
Jay D. Richards Officer of Subsidiary
Sold at will
$174.70K 3,506 at 49.83
8.9%
Not planned
3 Feb 2026
Harlan S Robins Chief Scientific Officer
Sold on a plan
$154.28K 8,120 at 19.00
0.7%
Planned (10b5-1)
3 Feb 2026
April Rieger Chief Lgl. & Admin Ofc., Sec
Sold at will
$150.91K 8,078 at 18.68
3.5%
Not planned
3 Feb 2026
Erika Ashley Fisher Chief Legal Officer
Sold on a plan
$148.36K 589 at 251.88
5.1%
Planned (10b5-1)
3 Feb 2026
Jason Drew Smith General Counsel
Sold at will 3×
$147.26K 7,479 at 19.69
12.7%
Not planned
3 Feb 2026
Mark Schoenberg Chief Medical Officer
Sold at will 3×
$145.17K 7,373 at 19.69
4.8%
Not planned
3 Feb 2026
Sandra Calvin SVP, Chief Accounting Officer
Sold at will
$139.18K 4,333 at 32.12
8.1%
Not planned
3 Feb 2026
Derek J Maetzold Pres. & Chief Exec. Officer
Sold on a plan
$127.72K 3,200 at 39.91
3.6%
Planned (10b5-1)
3 Feb 2026
Patrick John Finn President and COO
Sold at will
$125.99K 2,705 at 46.58
0.9%
Not planned
3 Feb 2026
Thomas C Indelicarto EVP, Gen Counsel & Secretary
Sold on a plan 2×
$124.04K 498 at 249.08
1.6%
Planned (10b5-1)
3 Feb 2026
Martina M.D. Flammer Chief Medical Officer
Sold on a plan
$123.84K 795 at 155.77
0.9%
Planned (10b5-1)
3 Feb 2026
Roger Adsett Chief Operating Officer
Sold at will
$123.53K 791 at 156.17
0.7%
Not planned
3 Feb 2026
David L. Roller Senior Vice President
Sold at will
$111.55K 2,092 at 53.32
6.7%
Not planned
3 Feb 2026
David Foehr Senior VP, Finance and PAO
Sold on a plan 2×
$111.12K 5,556 at 20.00
22.7%
Planned (10b5-1)
3 Feb 2026
Sold on a plan 2×
$109.90K 10,000 at 10.99
0.5%
Planned (10b5-1)
3 Feb 2026
R Nichole Sumner VP & Controller
Sold at will
$106.85K 4,750 at 22.49
16.1%
Not planned
3 Feb 2026
Michael Alexander Smith Chief Legal Officer
Sold at will
$100.01K 640 at 156.27
1.1%
Not planned
3 Feb 2026
Sunil Gupta VP of Operations
Sold at will 2×
$98.83K 2,168 at 45.58
2.2%
Not planned
3 Feb 2026
Sold on a plan
$96.50K 10,500 at 9.19
14.4%
Planned (10b5-1)
3 Feb 2026
Tamara L Schulz Chief Accounting Officer
Sold on a plan
$91.31K 1,527 at 59.80
1.5%
Planned (10b5-1)
3 Feb 2026
Jeffrey Adam Novack Secretary and General Counsel
Sold at will
$91.29K 4,441 at 20.56
3.4%
Not planned
3 Feb 2026
Chad M. Smith Pres & COO, Better Mortgage · indirect
Sold on a plan
$83.80K 3,097 at 27.06
14.3%
Planned (10b5-1)
3 Feb 2026
Steven Yi See Remarks
Sold on a plan
$80.33K 8,000 at 10.04
0.3%
Planned (10b5-1)
3 Feb 2026
Matthew Baker Turner Pres., Patient Affordability
Sold at will
$62.64K 15,057 at 4.16
3.2%
Not planned
3 Feb 2026
Daniel S. Lorrain Chief Scientific Officer
Sold on a plan 2×
$62.31K 4,170 at 14.94
2.6%
Planned (10b5-1)
3 Feb 2026
Kristopher R Westbrooks President & COO
Sold on a plan
$62.06K 2,951 at 21.03
1.5%
Planned (10b5-1)
3 Feb 2026
Emily Yang SVP Worldwide Sales/Marketing
Sold at will
$57.81K 950 at 60.85
1.3%
Not planned
3 Feb 2026
Lyra Amber Schramm Chief People Officer
Sold on a plan
$55.99K 199 at 281.37
52.9%
Sold half or more
3 Feb 2026
Paula Green SVP of Human Resources
Sold at will
$55.61K 1,194 at 46.58
0.7%
Not planned
3 Feb 2026
Timothy Keutzer Chief Operating Officer
Sold at will
$51.84K 24,224 at 2.14
3.1%
Not planned
3 Feb 2026
Dennis Cho See Remarks
Sold at will
$51.19K 1,099 at 46.58
0.8%
Not planned
3 Feb 2026
Rebecca L Charlton SVP, Controller & CAO
Sold on a plan
$47.49K 843 at 56.34
5.7%
Planned (10b5-1)
Showing 18,051–18,100 of 23,078. ← Newer Page 362 of 462 Older →